Vera Therapeutics transitioned to a commercial-stage company in the third quarter of 2026, reporting net product revenue of $10.3 million that significantly exceeded the consensus estimate of $3.9 million. This outperformance was driven by the initial U.S. launch of TRUTAKNA, while the reported net loss per share of $1.30 was narrower than the projected loss of $1.72.

Key Highlights

  • TRUTAKNA launch momentum is evidenced by $10.3 million in net revenue and approximately 700 Patient Start Forms received since its July accelerated approval.
  • ORIGIN 3 trial final efficacy analysis showed a 76% reduction in risk of composite kidney disease progression and stabilization of kidney function versus placebo over two years.
  • Robust liquidity position was reported with $384 million in cash as of September 30, pro-forma adjusted to $459 million following a $75 million debt draw in October.